Universal Growing $16.16 Bn Biodefense Market | Xoma Corporation, PharmAthene, Emergent BioSolutions, Dynavax Technologies Corporation, SIGA Technologies, Elusys Therapeutics, Ichor Medical Systems, DynPort Vaccine Company, Cleveland BioLabs, Bavarian Nor

Biodefense Market By Product - Global Industry Analysis and Forecast to 2022.

In 2012, the global biodefense market was evaluated around USD 7.98 billion and is expected to reach approximately USD 16.16 billion by 2022 while registering itself at a compound annual growth rate (CAGR) of 7.32% over the forecast period owing to technological developments in pathogen detection method in the forensic department.

Competitive Outlook and Trend Analysis:

Global biodefense market is comparatively less competitive owing to dedicated nature of the products, and small commercial products demand. The major industry players are Xoma Corporation, PharmAthene, Emergent BioSolutions, Dynavax Technologies Corporation, SIGA Technologies, Elusys Therapeutics, Ichor Medical Systems, DynPort Vaccine Company, Cleveland BioLabs, Bavarian Nordic, Achaogen, Nanotherapeutics, and Alnylam Pharmaceuticals.

Sample Copy of This Report: https://www.crystalmarketresearch.com/report-sample/HC11341 .

Industry Updates:

On October 15, 2018, Emergent, Wells Fargo Bank, National Association, as administrative agent (the Administrative Agent), and the lenders party thereto (the Lenders), entered into an Amended and Restated Credit Agreement, dated as of October 15, 2018 (the Amended Credit Agreement), which Amended Credit Agreement amended and restated Emergent's existing Credit Agreement, dated as of September 29, 2017, by and among Emergent, the Administrative Agent and certain of the Lenders.

Dynavax Technologies Corporation announced that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by Merck (known as MSD outside the United States and Canada).

SIGA Technologies, Inc. announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). This CRADA will focus on Good Laboratory Practice (GLP) studies of TPOXX® for post-exposure prophylaxis (PEP) using a U.S. Food and Drug Administration (FDA)-approved non-human primate model of TPOXX efficacy against smallpox infection. PEP regimens are designed to prevent infection in individuals who have known or potential exposure to an infectious agent but are not symptomatic.

PharmAthene, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the period, the company reported contract revenue of $804,071, loss from operations of $3,183,323, loss before income taxes of $3,198,912, net loss of $2,197,597 or $0.03 per basic and diluted share against contract revenue of $1,005,694, loss from operations of $1,254,436, loss before income taxes of $1,211,469, net loss of $1,226,906 or $0.02 per basic and diluted share a year ago.

XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific.

Industry Trend Analysis:

In 2012, the global biodefense market was evaluated around USD 7.98 billion and is expected to reach approximately USD 16.16 billion by 2022 while registering itself at a compound annual growth rate (CAGR) of 7.32% over the forecast period owing to technological developments in pathogen detection method in the forensic department. A few of the modern technologies employed in biodefense are nanotechnology, database management systems, advanced detector hardware, and gene chips. The rising vaccines production, quick diagnostic procedures, superior detection and forensic therapies, and prophylactics are amongst the crucial factors anticipated to reinforce the biodefense capabilities around the globe over the projected period. Escalating investment by the local government in developed economies, like the Europe and the United States, for biodefense awareness, is expected to boost the growth during the forecast years. According to the report issued by the Centre for Research on Innovation and Science Policy, it was affirmed that the number of grants owed by the National Institutes of Health (NIH) for the progress of bioweapon agents, like anthrax, plague, glanders, brucellosis, and tularemia, had augmented by 15 times over the years, 1996-2001.

The global biodefense market is segmented as follows –

By Product:

Anthrax
Smallpox
Botulism
Radiation/ nuclear defense
Others

Get More Information of This Report: https://www.crystalmarketresearch.com/report/biodefense-market .

Product Outlook and Trend Analysis:

In 2015, Anthrax was the leading application section and reported for a market share of around 31.3%.The rising interest, as well as attempts of private players in escalating the product range providing to anthrax prevention, is expected to drive the industry growth in the approaching years. Rising government investments in the United States to produce and stockpile adequate vaccines against anthrax during various programs, like Biomedical Advanced Research and Development Authority (BARDA), BioShield Legislation, and Joint Program Executive Office for Biological and Chemical Defense, is initiating commercial opportunities for this field. The other products section reported for approximately 15% of the overall market during 2015 and is anticipated to grow at a compound annual growth rate of around 8.3% during forecast period.

By Region:

North America - U.S, Canada, Mexico

Europe - Germany, France, UK, Italy, Spain, Rest of Europe

Asia-Pacific - Japan, China, Australia, India, South Korea, Rest of Asia Pacific

Rest of the World - Brazil, South Africa, Saudi Arabia, United Arab Emirates, Others

Regional Outlook and Trend Analysis:

In 2015, North American market appeared as the major segment reporting for over half of the global industry. Government initiatives concerning to the funding for genetic defense mechanism is a key factor pushing the expansion of the market. Though, fluctuations in financial support owing to altering government regulations might hamper demand over the forecast years. Asia Pacific region is anticipated to experience a major demand owing to rising investments in the R&D segment. Japan and Australia are a couple of the most developed Asia Pacific regional markets. The widespread vaccine production facilities offer across Japan along with the existence of advanced healthcare infrastructure in the nation is leading to its robust industry position.

List of Tables:

Table 1.Biodefense Market by Product ($Million), 2012-2022
Table 2.Anthrax Market, by Type ($Million), 2012-2022
Table 3.Smallpox Market, by Region ($Million), 2012-2022
Table 4.Botulism Market, by Region ($Million), 2012-2022
Table 5.Radiation/ nuclear defense Market, by Region ($Million), 2012-2022
...

List of Figures:

Figure 1.Biodefense Market Share, by Product, 2016 & 2025
Figure 2Biodefense Market by Region, 2016, ($Million)
Figure 3.Xoma Corporation: Net Revenues, 2014-2016 ($Million)
Figure 4.Xoma Corporation: Net Revenue Share, by Segment, 2016
Figure 5.Xoma Corporation: Net Revenue Share, by Geography, 2016
...

Check Best Offer of This Report: https://www.crystalmarketresearch.com/check-discount/HC11341 .

TO BE CONTINUED…

About Crystal Market Research:

Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customised research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy.

Contact Us:
Judy
304 South Jones Blvd, Suite 1896,
Las Vegas NV 89107,
United States
Toll Free: +1-888-213-4282
Email: sales@crystalmarketresearch.com

This release was published on openPR.